… Patients with grade 2 or more skin toxicity on erlotinib monotherapy were not eligible. The
… growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib …

… and erlotinib exposure in non-small cell lung cancer patients treated with single-agent
erlotinib. … By use of erlotinib monotherapy as a reference, CL/F was 10.5% and 18.1% faster in …

… IV study of erlotinib, designed to allow access to erlotinib monotherapy for patients with …
for other erlotinib trials. In each country, recruitment continued until erlotinib was granted a …

… Conclusions: Erlotinib is active and well tolerated as first-line monotherapy in advanced
NSCLC. Responses were seen in … Further assessment of erlotinib in this setting is warranted. …

… In phase II clinical studies, oral erlotinib monotherapy has shown antitumor activity in
patients with advanced non–small cell lung cancer, head and neck cancer, and ovarian cancer …

… The aim of this study was to review the treatment response of erlotinib monotherapy in …
with erlotinib monotherapy during January 2006 to October 2011. We included lung cancer …

… was 34% with erlotinib monotherapy compared with 47% with erlotinib and chemotherapy.
The … predictors of erlotinib efficacy in advanced non-small cell lung cancer? Clin Cancer Res …

… Third, although 10 recent well-designed RCTs were included, until this meta-analysis no
data focusing on the merits of erlotinib plus bevacizumab over monotherapy in EGFR- or KRAS-…

… (EGFR TKIs), such as erlotinib and gefitinib, have demonstrated … more effective than standard
monotherapy with cytotoxics in the … data on erlotinib in the treatment of advanced NSCLC. …

Purpose. Epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer has
an oncogene‐addicted biology that confers sensitivity to EGFR tyrosine kinase inhibitors (TKIs…